Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
DXI Capital ( (TSE:VVTM) ) has provided an update.
VVT Med Inc. has secured an initial order for its ScleroSafe™ technology from Northwell Health, a major U.S. healthcare network, marking a significant entry into the U.S. public hospital market. This milestone is expected to enhance VVT’s market positioning and serve as a reference for other hospitals considering the product. Additionally, VVT has entered into investor relations agreements with I3 Capital Group and Revolution Small Cap Marketing to increase awareness and support its growth plans in North America.
More about DXI Capital
VVT Med Inc. is a company specializing in the manufacturing of next-generation, minimally-invasive treatments for varicose veins. Their flagship product, ScleroSafe™, is designed to streamline varicose vein procedures without the need for anesthetics or significant capital investment, making treatments more accessible and reducing patient discomfort.
Average Trading Volume: 28,037
Technical Sentiment Signal: Buy
For a thorough assessment of VVTM stock, go to TipRanks’ Stock Analysis page.